The murine Version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe Mice

Journal of Alzheimer's Disease

Volumn 43, Issue 2, 2015, Pages 575-588

  Tucker, Stina ^a   Möller, Christer ^a   Tegerstedt, Karin ^a   Lord, Anna ^a   Laudon, Hanna ^a   Sjödahl, Johan ^a   Söderberg, Linda ^a   Spens, Erika ^a   Sahlin, Charlotte ^a   Waara, Erik Rollman ^a   Satlin, Andrew ^b   Gellerfors, Pär ^a   Osswald, Gunilla ^a   Lannfelt, Lars ^a,c  

^a BioArctic Neuroscience   (Sweden)

^b EISAI INC   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Alzheimer's disease; amyloid ; antibody; BAN2401; biomarker; cerebrospinal fluid; immunotherapy; mAb158; oligomer; protofibrils

Indexed keywords

AMYLOID BETA PROTEIN; BAN 2401; BRAIN EXTRACT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 158; MONOMER; OLIGOMER; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN; IMMUNOLOGIC FACTOR; PRESENILIN 1; PROTEIN BINDING; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; BRAIN; CEREBROSPINAL FLUID; DRUG POTENCY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PROTEIN AGGREGATION; SURFACE PLASMON RESONANCE; AMYLOID PLAQUE; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPRECIPITATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLAQUE, AMYLOID; PRESENILIN-1; PROTEIN BINDING;

EID: 84911943239     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140741     Document Type: Article

References (68)

1. Golde T, Eckman CB, Younkin SG (2000) Biochemicaldetection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer's disease. Biochim BiophysActa 1502, 172-187.
2. Walsh DM, Teplow DB (2012) Alzheimer's disease and theamyloid beta-protein. Prog Mol Biol Transl Sci 107, 101-124.
3. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The C-terminusof the beta protein is critical in amyloidogenesis. Ann N YAcad Sci 695, 144-148.
4. Jarrett JT, Berger EP, Lansbury PT Jr (1993) The carboxyterminus of the beta amyloid protein is critical for the seedingof amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693-4697.
5. Katzman R, Terry R, DeTeresa R, Brown T, Davies P, Fuld P, Renbing X, Peck A (1988) Clinical, pathological, and neurochemicalchanges in dementia: A subgroup with preservedmental status and numerous neocortical plaques. Ann Neurol23, 138-144.
6. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, Hansen LA, Katzman R (1991) Physical basis ofcognitive alterations in Alzheimer's disease: Synapse loss isthe major correlate of cognitive impairment. Ann Neurol 30, 572-580.
7. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediatesof amyloid beta-protein induce acute electrophysiologicalchanges and progressive neurotoxicity in cortical neurons. JNeurosci 19, 8876-8884.
8. Walsh DM, Klyubin I, Fadeeva JV, William K, Cullen W, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturallysecreted oligomers of the Alzheimer amyloid beta-proteinpotently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539.
9. Klyubin I, Walsh DM, Cullen WK, Fadeeva JV, Anwyl R, Selkoe DJ, Rowan MJ (2004) Soluble Arctic amyloid betaprotein inhibits hippocampal long-term potentiation in vivo. Eur J Neurosci 19, 2839-2846.
10. Whalen BM, Selkoe DJ, Hartley DM (2005) Small nonfibrillarassemblies of amyloid beta-protein bearing the Arcticmutation induce rapid neuritic degeneration. Neurobiol Dis20, 254-266.
11. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ (2006) Effects of secreted oligomers of amyloid beta-proteinon hippocampal synaptic plasticity: A potent role for trimers. J Physiol 572, 477-492.
12. Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM (2007) Abeta oligomer-mediated long-term potentiationimpairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 27, 7648-7653.
13. Lacor PN, Buniel MC, Furlow PW, Clemente AS, Velasco PT, Wood M, Viola KL, Klein WL (2007) Abeta oligomerinducedaberrations in synapse composition, shape, anddensity provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27, 796-807.
14. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL (2007) Natural oligomers of theAlzheimer amyloid-beta protein induce reversible synapseloss by modulating an NMDA-type glutamate receptordependentsignaling pathway. J Neurosci 27, 2866-2875.
15. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM (2010) Amyloid betaproteindimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30, 14411-14419.
16. Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM (2002) Immunization reverses memory deficits withoutreducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5, 452-457.
17. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, Younkin S, Ashe KH (2002) Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 22, 6331-6335.
18. Lue L-F, Kuo Y-M, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J (1999) Soluble amyloid-peptide concentration as a predictor of synaptic changein Alzheimer's disease. Am J Pathol 155, 853-862.
19. McLean C, Cherny R, Fraser F, Fuller S, Smith M, Beyreuther K, Bush A, MastersC (1999) Soluble pool of Abeta amyloid asa determinant of severity of neurodegeneration in Alzheimer'sdisease. Ann Neurol 46, 860-866.
20. Wang J, Dickson DW, Trojanowski JQ, Lee VM (1999) Thelevels of soluble versus insoluble brain Abeta distinguishAlzheimer's disease from normal and pathologic aging. ExpNeurol 158, 328-337.
21. Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, Frebourg T, Checler F (1999) Unusual phenotypicalteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715-Met betaAPP-770 mutationresponsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci USA 96, 4119-4124.
22. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Näslund J, Lannfelt L (2001) TheAP Pmutation (E693G) causes Alzheimer's disease by enhancedAbeta protofibril formation. Nat Neurosci 4, 887-893.
23. Lashuel HA, Hartley DM, Petre BM, Wall JS, Simon MN, Walz T, Lansbury PT (2003) Mixtures of wild-type and apathogenic (E22G) form ofA-40 in vitro accumulate protofibrils, including amyloid pores. J Mol Biol 332, 795-808.
24. Johansson AS, Berglind-Dehlin F, Karlsson G, Edwards K, Gellerfors P, Lannfelt L (2006) Physiochemical characterizationof the Alzheimer's disease-related peptides Abeta1-42Arctic and Abeta 1-42wt. FEBS J 273, 2618-2630.
25. Schöll M, Wall A, Thordardottir S, Ferreira D, Bogdanovic N, Långström B, Almkvist O, Graff C, Nordberg A (2012) LowPiB PET retention in presence of pathologic CSF biomarkersin Arctic APP mutation carriers. Neurology 79, 229-236.
26. Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Lomakin A, Benedek GB, Condron MM, Teplow DB (1997) Amyloidbeta-protein fibrillogenesis. J Biol Chem 272, 22364-22372.
27. Sehlin D, Englund H, Simu B, Karlsson M, Ingelsson M, Nikolajeff F, Lannfelt L, Ekholm Pettersson F (2012) Largeaggregates are the major soluble Abeta species in AD brainfractionated with density gradient ultracentrifugation. PloSOne 7, e32014.
28. Lord A, Englund H, Söderberg L, Tucker S, Clausen F, Hillered L, Gordon M, Morgan D, Lannfelt L, Ekholm Pettersson F, Nilsson LNG (2009) Amyloid-beta protofibril levelscorrelate with spatial learning in Arctic Alzheimer's diseasetransgenic mice. FEBS J 276, 995-1006.
29. May PC, Dean RA, Lowe SL, Martenyi F, Sheehan SM, Boggs LN, Monk SA, Mathes BM, Mergott DJ, Watson BM, Stout SL, Timm DE, Smith Labell E, Gonzales CR, Nakano M, Jhee SS, Yen M, Ereshefsky L, Lindstrom TD, Calligaro DO, Cocke PJ, Greg Hall D, Friedrich S, Citron M, Audia JE (2011) Robust central reduction of amyloid-beta in humanswith an orally available, non-peptidic beta-secretase inhibitor. J Neurosci 31, 16507-16516.
30. D'Onofrio G, Panza F, Frisardi V, Solfrizzi V, Imbimbo BP, Paroni G, Cascavilla L, Seripa D, Pilotto A (2012) Advancesin the identification of gamma-secretase inhibitors for thetreatment of Alzheimer's disease. Expert Opin Drug Discov7, 19-37.
31. Cai J, Qi X, Kociok N, Skosyrski S, Emilio A, Ruan Q, Han S, Liu L, Chen Z, Bowes Rickman C, Golde T, Grant MB, Saftig P, Serneels L, de Strooper B, Joussen AM, BoultonME (2012) beta-Secretase (BACE1) inhibition causes retinalpathology by vascular dysregulation and accumulation of agepigment. EMBO Mol Med 4, 980-991.
32. Willem M, Garratt AN, Novak B, Citron M, Kaufmann S, Rittger A, DeStrooper B, Saftig P, Birchmeier C, Haass C (2006) Control of peripheral nerve myelination by the betasecretaseBACE1. Science 314, 664-666.
33. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P (1999) Immunization withamyloid-beta attenuates Alzheimer-disease-like pathology inthe PDAPP mouse. Nature 400, 173-177.
34. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodiesagainst amyloid beta-peptide enter the central nervous systemand reduce pathology in a mouse model of Alzheimerdisease. Nat Med 6, 916-919.
35. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, StGeorge-Hyslop P, Westaway D (2000) Abeta peptide immunizationreduces behavioural impairment and plaques in amodel of Alzheimer's disease. Nature 408, 979-982.
36. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, ArendashGW (2000) Abetapeptide vaccination prevents memory loss in an animal modelof Alzheimer's disease. Nature 408, 982-985.
37. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-Abeta antibody altersCNS and plasma Abeta clearance and decreases brain Abetaburden in a mouse model of Alzheimer's disease. Proc NatlAcad Sci USA 98, 8850-8855.
38. Rasool S, Martinez-Coria H, Wu JW, LaFerla F, Glabe CG (2013) Systemic vaccination with anti-oligomeric monoclonalantibodies improves cognitive function by reducing Abeta deposition and tau pathology in 3xTg-AD mice. J Neurochem126, 473-482.
39. Zago W, Buttini M, Comery TA, Nishioka C, Gardai SJ, Seubert P, Games D, Bard F, Schenk D, Kinney GG (2012) Neutralization of soluble, synaptotoxic amyloid beta speciesby antibodies is epitope specific. J Neurosci 32, 2696-2702.
40. Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute meningoencephalitisin a subset of patients with AD after Abeta42immunization. Neurology 61, 46-54.
41. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, Tompkins C, Leibman C, Pomfret M, Grundman M (2009) Long-term follow-up of patients immunized withAN1792: Reduced functional decline in antibody responders. Curr Alzheimer Res 6, 144-151.
42. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM (2003) Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554.
43. Lannfelt L, Relkin NR, Siemers ER (2014) Amyloid-betadirected immunotherapy for Alzheimer's disease. J Intern Med 275, 284-295.
44. Monsonego A, Imitola J, Zota V, Oida T, Weiner HL (2003) Microglia-mediated nitric oxide cytotoxicity ofTcells followingamyloid beta-peptide presentation to Th1 cells. J Immunol171, 2216-2224.
45. An Z (2010) Monoclonal antibodies-a proven and rapidlyexpanding therapeutic modality for human diseases. ProteinCell 1, 319-330.
46. Blennow K, Zetterberg H, Rinne J, Salloway S, Wei J, Black R, Grundman M, Liu E (2012) Effect of immunotherapywith bapineuzumab on cerebrospinal fluid biomarker levelsin pateints with mild to moderate Alzheimer disease. ArchNeurol 69, 1002-1010.
47. Rinne J, Brooks D, Rossor M, Fox N, Bullock R, Klunk W, Mathis C, Blennow K, Barakos J, Okello A, Rodriguez Martinezde Liano S, Liu E, Koller M, Gregg K, Schenk D, Black R, Grundman M (2010) 11C-PiBPETassessment of change infibrillar amyloid-beta load in patients with Alzheimer's diseasetreated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending dose study. Lancet Neurol 9, 363-372.
48. Lobello K, Ryan JM, Liu E, Rippon G, Black R (2012) Targetingbeta-amyloid: A clinical review of immunotherapeuticapproaches in Alzheimer's disease. Int J Alzheimers Dis 2012, 628070.
49. Lannfelt L, Möller C, Basun H, Osswald G, Sehlin D, Satlin A, Logovinsky V, Gellerfors P (2014) Perspectives on futureAlzheimer therapies: Amyloid-beta protofibrils-a newtargetfor immunotherapy with BAN2401 in Alzheimer's disease. Alzheimers Res Ther 6, 16.
50. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR, Bapineuzumab, ClinicalTrial I (2014) Two phase 3 trials of bapineuzumab inmild-to-moderate Alzheimer's disease. N Engl J Med 370, 322-333.
51. Englund H, Sehlin D, Johansson AS, Nilsson LN, Gellerfors P, Paulie S, Lannfelt L, Pettersson FE (2007) Sensitive ELIS Adetection of amyloid-beta protofibrils in biological samples. J Neurochem 103, 334-345.
52. Lord A, Kalimo H, Eckman CB, Zhang X-Q, Lannfelt L, Nilsson LNG (2006) The Arctic Alzheimer mutation facilitatesearly intraneuronal Abeta aggregation and senile plaqueformation in transgenic mice. Neurobiol Aging 27, 67-77.
53. Neri D, Montigiani S, Kirkham PM (1996) Biophysicalmethods for the determination of antibody-antigen affinities. Trends Biotechnol 14, 465-470.
54. Lord A, Gumucio A, Englund H, Sehlin D, ScrepantiSundquist V, Söderberg L, Möller C, Gellerfors P, Lannfelt L, Ekholm Pettersson F, Nilsson LNG (2009) An amyloid-betaprotofibril-selective antibody prevents amyloid formation ina mouse model of Alzheimer's disease. Neurobiol Dis 36, 425-434.
55. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum J (2000) Correlation between elevatedlevels of amyloid beta-peptide in the brain and cognitivedecline. JAMA 283, 1571-1577.
56. Hillen H, Barghorn S, Striebinger A, Labkovsky B, Muller R, Nimmrich V, Nolte MW, Perez-Cruz C, van der Auwera I, van Leuven F, van Gaalen M, Bespalov AY, Schoemaker H, Sullivan JP, Ebert U (2010) Generation and therapeuticefficacy of highly oligomer-specific beta-amyloid antibodies. J Neurosci 30, 10369-10379.
57. Bohrmann B, Baumann K, Benz J, Gerber F, Huber W, Knoflach F, Messer J, Oroszlan K, Rauchenberger R, Richter WF, Rothe C, Urban M, Bardroff M, Winter M, Nordstedt C, Loetscher H (2012) Gantenerumab: A novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-betabinding and elicits cell-mediated removal of human amyloidbeta. J Alzheimers Dis 28, 49-69.
58. Minami SS, Sidahmed E, Aid S, Shimoji M, Niikura T, Mocchetti I, Rebeck GW, Prendergast JS, Dealwis C, Wetzel R, Bosetti F, Matsuoka Y, Hoe HS, Turner RS (2010) Therapeuticversus neuroinflammatory effects of passive immunizationis dependent on Abeta/amyloid burden in a transgenic mousemodel of Alzheimer's disease. J Neuroinflammation 7, 57.
59. Adolfsson O, Pihlgren M, Toni N, Varisco Y, Buccarello AL, Antoniello K, Lohmann S, Piorkowska K, Gafner V, Atwal JK, Maloney J, Chen M, Gogineni A, Weimer RM, Mortensen DL, Friesenhahn M, Ho C, Paul R, Pfeifer A, Muhs A, WattsRJ (2012) An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotectionand glial engulfment of Abeta. J Neurosci 32, 9677-9689.
60. Gardberg AS, Dice LT, Ou S, Rich RL, Helmbrecht E, Ko J, Wetzel R, Myszka DG, Patterson PH, Dealwis C (2007) Molecular basis for passive immunotherapy of Alzheimer'sdisease. Proc Natl Acad Sci USA 104, 15659-15664.
61. Kayed R, Canto I, Breydo L, Rasool S, Lukacsovich T, Wu J, Albay R, 3rd, Pensalfini A, Yeung S, Head E, Marsh JL, Glabe C (2010) Conformation dependent monoclonal antibodiesdistinguish different replicating strains or conformersof prefibrillar Abeta oligomers. Mol Neurodegener 5, 57.
62. Magnusson K, Sehlin D, Syvänen S, Svedberg MM, Philipson O, Söderberg L, Tegerstedt K, Holmquist M, Gellerfors P, Tolmachev V, Antoni G, Lannfelt L, Hall H, NilssonLN (2013) Specific uptake of an amyloid-beta protofibrilbindingantibody-tracer in AbetaPP transgenic mouse brain. J Alzheimers Dis 37, 29-40.
63. Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo Y-M, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castaño EM, Roher AE (2006) Amyloid-peptide remnants in AN-1792-immunizedAlzheimer's disease patients. Am J Pathol 169, 1048-1063.
64. Racke MM, Boone LI, Hepburn DL, Parsadainian M, Bryan MT, Ness DK, Piroozi KS, Jordan WH, Brown DD, Hoffman WP, Holtzman DM, Bales KR, Gitter BD, May PC, Paul SM, DeMattos RB (2005) Exacerbation of cerebral amyloidangiopathy-associated microhemorrhage in amyloid precursorprotein transgenic mice by immunotherapy is dependenton antibody recognition of deposited forms of amyloid beta. J Neurosci 25, 629-636.
65. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M (2002) Cerebral hemorrhageafter passive anti-Abeta immunotherapy. Science 298, 1379.
66. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D (2004) Passive immunotherapyagainst Abeta in aged APP-transgenic mice reverses cognitivedeficits and depletes parenchymal amyloid deposits inspite of increased vascular amyloid and microhemorrhage. JNeuroinflammation 1, 24.
67. Wilcock DM, Alamed J, Gottschall PE, Grimm J, Rosenthal A, Pons J, Ronan V, Symmonds K, Gordon MN, MorganD (2006) Deglycosylated anti-amyloid-beta antibodies eliminatecognitive deficits and reduce parenchymal amyloid withminimal vascular consequences in aged amyloid precursorprotein transgenic mice. J Neurosci 26, 5340-5346.
68. Fenyk-Melody JE, Shen X, Peng Q, Pikounis W, Colwell L, Pivnichny J, Anderson LC, Tamvakopoulos CS (2004) Comparison of the effects of perfusion in determining brainpenetration (brain-to-plasma ratios) of small molecules inrats. Comp Med 54, 378-381.